Structure-based receptor MIMICS targeted against bacterial superantigen toxins
    1.
    发明授权
    Structure-based receptor MIMICS targeted against bacterial superantigen toxins 失效
    针对细菌超抗原毒素的基于结构的受体MIMICS

    公开(公告)号:US07576183B2

    公开(公告)日:2009-08-18

    申请号:US10746959

    申请日:2003-12-24

    Abstract: The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class II receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen “receptor mimetics” or “chimeras” are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.

    Abstract translation: 本发明提供治疗组合物,其可用于治疗细菌超抗原介导的病症,例如有毒性休克综合症。 所述组合物包含含有特异性T细胞受体结合结构域和特异性MHC II类受体结合结构域的遗传工程改造的双功能多肽,每个靶向它们设计在其上的超抗原分子上的非重叠表位。 合成设计抗超抗原“受体模拟物”或“嵌合体”,以重新形成超抗原结合直接与TCR和MHC-II受体结合的模式,并且能够作为超抗原结合的诱饵,有效地竞争 宿主T细胞和MHC-II受体,天然宿主受体。

    Compositions and methods for the treatment of Pierce's disease
    2.
    发明授权
    Compositions and methods for the treatment of Pierce's disease 有权
    皮尔斯病治疗的组合和方法

    公开(公告)号:US07432419B2

    公开(公告)日:2008-10-07

    申请号:US10846172

    申请日:2004-05-14

    Applicant: Goutam Gupta

    Inventor: Goutam Gupta

    CPC classification number: C12N15/8281 C07K14/43563 C07K14/4723 C07K2319/00

    Abstract: Chimeric anti-microbial proteins, compositions, and methods for the therapeutic and prophylactic treatment of plant diseases caused by the bacterial pathogen Xylella fastidiosa are provided. The anti-microbial proteins of the invention generally comprise a surface recognition domain polypeptide, capable of binding to a bacterial membrane component, fused to a bacterial lysis domain polypeptide, capable of affecting lysis or rupture of the bacterial membrane, typically via a fused polypeptide linker. In particular, methods and compositions for the treatment or prevention of Pierce's disease of grapevines are provided. Methods for the generation of transgenic Vitus vinefera plants expressing xylem-secreted anti-microbial chimeras are also provided.

    Abstract translation: 提供了用于治疗和预防由细菌病原体Xylella fastidiosa引起的植物疾病的嵌合抗微生物蛋白质,组合物和方法。 本发明的抗微生物蛋白质通常包含能够结合细菌膜组分的表面识别结构域多肽,细菌膜组分与细菌裂解结构域多肽融合,能够影响细菌膜的裂解或破裂,通常通过融合的多肽接头 。 特别地,提供了用于治疗或预防葡萄藤皮尔斯氏病的方法和组合物。 还提供了用于产生表达木质部分泌的抗微生物嵌合体的转基因藤蔓植物的方法。

    Preparation of 13C/15N-labeled oligomers using the polymerase chain reaction
    3.
    发明授权
    Preparation of 13C/15N-labeled oligomers using the polymerase chain reaction 失效
    使用聚合酶链反应制备13C / 15N标记的寡聚体

    公开(公告)号:US06258567B1

    公开(公告)日:2001-07-10

    申请号:US09322899

    申请日:1999-05-29

    CPC classification number: C12Q1/6844

    Abstract: Preparation of 13C/15N-labeled DNA oligomers using the polymerase chain reaction (PCR). A PCR based method for uniform (13C/15N)-labeling of DNA duplexes is described. Multiple copies of a blunt-ended duplex are cloned into a plasmid, each copy containing the sequence of interest and restriction Hinc II sequences at both the 5′ and 3′ ends. PCR using bi-directional primers and uniformly 13C/15N-labeled dNTP precursors generates labeled DNA duplexes containing multiple copies of the sequence of interest. Twenty-four cycles of PCR, followed by restriction and purification, gave the uniformly 13C/15N-labeled duplex sequence with a 30% yield. Such labeled duplexes find significant applications in multinuclear magnetic resonance spectroscopy.

    Abstract translation: 使用聚合酶链反应(PCR)制备13C / 15N标记的DNA寡聚体。 描述了用于DNA双链体的均一(13C / 15N)标记的基于PCR的方法。 将平头端双链体的多个拷贝克隆到质粒中,每个拷贝在5'和3'末端都含有目的序列和限制性Hinc II序列。 使用双向引物和均匀的13C / 15N标记的dNTP前体的PCR产生包含感兴趣序列的多个拷贝的标记的DNA双链体。 二十四个循环的PCR,然后进行限制和纯化,得到均匀的13C / 15N标记的双链体序列,产率为30%。 这种标记的双链体在多核磁共振光谱中发现显着的应用。

    Curable coating compositions comprising self-crosslinkable components
    4.
    发明授权
    Curable coating compositions comprising self-crosslinkable components 失效
    包含自交联组分的可固化涂料组合物

    公开(公告)号:US4983266A

    公开(公告)日:1991-01-08

    申请号:US290620

    申请日:1988-12-27

    CPC classification number: C09D5/4411 Y10S524/901

    Abstract: This invention relates to an electrodeposition process which comprises electrodepositing onto a conducting substrate a coating composition comprising a self-crosslinking polymeric resin which has an average of at least two pendent hydroxy functional groups and an average of at least two pendent ester groups of the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl, substituted alkyl or aryl groups; n is from about 1 to about 5; X is nitrogen, sulfur or phosphorus; and when X is nitrogen or phosphorus, R.sup.3 is hydrogen, lower alkyl, or an aryl group; R.sup.4 is lower alkyl or an aryl group; and when X is sulfur, R.sup.4 is nothing and R.sup.3 is either hydrogen, lower alkyl or aryl.

    Abstract translation: 电沉积方法本发明涉及一种电沉积方法,其包括在导电基材上电沉积包含自交联聚合物树脂的涂料组合物,所述自交联聚合物树脂平均具有至少两个侧链羟基官能团和平均至少两个通式 (Ⅰ)其中R1和R2独立地是氢,烷基,取代的烷基或芳基; n为约1至约5; X是氮,硫或磷; 当X是氮或磷时,R 3是氢,低级烷基或芳基; R4是低级烷基或芳基; 当X为硫时,R 4为无,R 3为氢,低级烷基或芳基。

    Process for producing organophilic silica
    5.
    发明授权
    Process for producing organophilic silica 失效
    亲有机硅的生产方法

    公开(公告)号:US4644077A

    公开(公告)日:1987-02-17

    申请号:US777461

    申请日:1985-09-18

    Applicant: Goutam Gupta

    Inventor: Goutam Gupta

    CPC classification number: C01B33/149 C09C1/3081 C01P2004/60 C01P2006/22

    Abstract: In a silica organosol consisting of silica dispersed in a water-miscible organic solvent, a process for treating the silica with a trialkoxysilane to make the silica more organophilic while minimizing the self condensation of the trialkoxy silane, which process comprises:(a) admixing water and a catalytic amount of acid to the silica organosol; and(b) gradually adding a trialkoxysilane to the admixture under reactive conditions; and(c) removing substantially all of the water;wherein the trialkoxy silane is present at a level up to about 30% by weight based upon the weight of the silica and the water is added at an amount up to about 30% by weight based upon the weight of the water-miscible organic solvent.

    Abstract translation: 在由分散在与水可混溶的有机溶剂中的二氧化硅组成的二氧化硅有机溶胶中,使用三烷氧基硅烷处理二氧化硅以使二氧化硅更亲有亲和同时最小化三烷氧基硅烷的自缩合的方法,该方法包括:(a)混合水 和催化量的酸对二氧化硅有机溶胶; 和(b)在反应条件下向混合物中逐渐加入三烷氧基硅烷; 和(c)基本上除去所有的水; 其中三烷氧基硅烷以基于二氧化硅的重量计高达约30重量%的量存在,并且基于水混溶性有机溶剂的重量,加入水的量高达约30重量%。

    Structure-based receptor MIMICS targeted against bacterial superantigen toxins
    6.
    发明申请
    Structure-based receptor MIMICS targeted against bacterial superantigen toxins 失效
    针对细菌超抗原毒素的基于结构的受体MIMICS

    公开(公告)号:US20050260222A1

    公开(公告)日:2005-11-24

    申请号:US10746959

    申请日:2003-12-24

    Abstract: The invention provides therapeutic compositions useful in the treatment of bacterial superantigen mediated conditions, such as Toxic Shock Syndrome. The compositions comprise genetically engineered bifunctional polypeptides containing a specific T-cell receptor binding domain and a specific MHC class 11 receptor binding domain, each targeting non-overlapping epitopes on a superantigen molecule against which they are designed. The anti-superantigen “receptor mimetics” or “chimeras” are rationally designed to recreate the modality of superantigen binding directly to both the TCR and the MHC-II receptor, and are capable of acting as decoys for superantigen binding, effectively out-competing the host T-cell and MHC-II receptors, the natural host receptors.

    Abstract translation: 本发明提供治疗组合物,其可用于治疗细菌超抗原介导的病症,例如有毒性休克综合症。 所述组合物包含含有特异性T细胞受体结合结构域和特异性MHC 11类受体结合结构域的遗传工程改造的双功能多肽,每个靶向靶向它们被设计的超抗原分子上的非重叠表位。 合成设计抗超抗原“受体模拟物”或“嵌合体”,以重新形成超抗原结合直接与TCR和MHC-II受体结合的模式,并且能够作为超抗原结合的诱饵,有效地竞争 宿主T细胞和MHC-II受体,天然宿主受体。

    Curable coating compositions comprising crosslinked components
    7.
    发明授权
    Curable coating compositions comprising crosslinked components 失效
    包含交联组分的可固化涂料组合物

    公开(公告)号:US4973392A

    公开(公告)日:1990-11-27

    申请号:US290213

    申请日:1988-12-27

    Applicant: Goutam Gupta

    Inventor: Goutam Gupta

    Abstract: This invention relates to coating compositions which comprise a polymer having at least two hydroxy functional groups and a crosslinking agent having an average of at least two pendent ester groups of the general formula: ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, alkyl, substituted alkyl or aryl groups; n is from about 1 to about 5; X is nitrogen, sulfur or phosphorus; and when X is either nitrogen or phosphorus, R.sup.3 is hydrogen, lower alkyl, or an aryl group; R.sup.4 is lower alkyl or an aryl group; and when X is sulfur, R.sup.4 is nothing and R.sup.3 is either hydrogen, lower alkyl or aryl.

    Abstract translation: 本发明涉及涂料组合物,其包含具有至少两个羟基官能团的聚合物和具有平均具有以下通式的至少两个侧链酯基的交联剂:其中R 1和R 2独立地为氢, 烷基,取代的烷基或芳基; n为约1至约5; X是氮,硫或磷; 当X为氮或磷时,R 3为氢,低级烷基或芳基; R4是低级烷基或芳基; 当X为硫时,R 4为无,R 3为氢,低级烷基或芳基。

    Acylated hindered hexahydropyrimidines and their use as light
stabilizing agents
    9.
    发明授权
    Acylated hindered hexahydropyrimidines and their use as light stabilizing agents 失效
    酰化受阻的六氢嘧啶及其作为光稳定剂的用途

    公开(公告)号:US4404302A

    公开(公告)日:1983-09-13

    申请号:US382556

    申请日:1982-05-27

    CPC classification number: C07D239/06 C07D239/04 C07D239/70 C08K5/3462

    Abstract: An acylated, hindered hexahydropyrimidine of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be the same or different independently of each other and are alkyl having 1 to 6 carbon atoms, when unsubstituted, or alkyl or aryl substituted;R.sub.5 and R.sub.6 may be the same or different and are hydrogen, or alkyl;R.sub.7 is selected from the group consisting of: alkyl having 1 to 20 carbon atoms, substituted alkyl where the alkyl without substitution has 1 to 20 carbon atoms and where substituents may be up to five lower alkyl groups, arylalkyl, cycloalkyl having 3 to 12 carbon atoms, aryl aryl substituted with 1 to 3 substituents seleted from the group consisting of: lower alkyl, lower alkoxy, and hydroxyl; ##STR2## wherein R.sub.9 is unsubstituted or substituted with alkyl,R.sub.10 is hydroxyl, lower alkoxy, phenoxy and the group ##STR3## and R.sub.8 is hydrogen, alkyl, substituted alkyl, arylalkyl, hydroxyl, oxyl and ##STR4## wherein R.sub.11 is unsubstituted or substituted alkyl.

    Abstract translation: 其中R 1,R 2,R 3和R 4可以彼此相同或不同,是未取代的烷基或芳基取代的具有1-6个碳原子的烷基;酰基化受阻的六氢嘧啶,其中R 1,R 2, R5和R6可以相同或不同,为氢或烷基; R 7选自:具有1至20个碳原子的烷基,取代的烷基,其中无取代的烷基具有1至20个碳原子,并且其中取代基可以多至五个低级烷基,芳基烷基,具有3-12个碳原子的环烷基 原子,被1至3个由低级烷基,低级烷氧基和羟基组成的组中选出的取代基取代的芳基芳基; 其中R 9未被取代或被烷基取代,R 10是羟基,低级烷氧基,苯氧基和基团,并且R 8是氢,烷基,取代的烷基,芳基烷基,羟基,氧基和 取代的烷基。

Patent Agency Ranking